Skip to main content
spacbrain

TriSalus Life Sciences

Closed (deSPAC)

Health Care · oncology drug delivery technology and immunotherapeutics

What it is
Life Sciences TriSalus Life Sciences® is an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors
What it’s doing now
Merging with MedTech Acquisition Corp (MTAC) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Life Sciences TriSalus Life Sciences® is an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. The company works to enable more patients to benefit from established and emerging cancer treatments by overcoming intratumoral pressure and immunosuppression, significant barriers that can limit delivery and efficacy. The proprietary TriSalus delivery method—Pressure-Enabled Drug Delivery ™ (PEDD ™ )—modulates pressure and flow within blood vessels to improve therapy uptake and tumor response in ways traditional approaches cannot. Two FDA-cleared devices utilize TriSalus’ proprietary approach to delivery of therapeutics: the TriNav® Infusion System and the Pancreatic Retrograde Venous Infusion ™ (PRVI ™ ) System. Currently in clinical trials across multiple indications, the TriSalus ™ Platform uses PEDD ™ to administer the company's investigational immunotherapy, SD-101, through a regional intravascular approach with the goal of strengthening immunotherapy responses for liver and pancreatic cancer patients. In partnership with leading cancer centers across the country, and by leveraging deep immuno-oncology expertise and inventive technology development, TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and LinkedIn .

Source: S-4/A, accession 0001641172-25-018793

What the company says about itself

Web research — not audited

TriSalus Life Sciences is developing a transformative platform to address barriers to the treatment of liver and pancreatic tumors, specifically focusing on overcoming intratumoral pressure and immunosuppressive environments. Their approach combines nelitolimod (SD-101), a selective toll-like receptor agonist, with their Pressure-Enabled Drug Delivery (PEDD) method to enable systemic immunotherapies like checkpoint inhibitors.

Markets:
Liver Tumors | Pancreatic Tumors | Oncology | Immunotherapy
Products:
nelitolimod (SD-101) | Pressure-Enabled Drug Delivery™ (PEDD™) | TriSalus™ platform
What our web check found

[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "As previously announced on November 14, 2022, TriSalus has entered into a definitive merger agreement with MedTech (the “Merger Agreement”), a publicly traded ..." [https://investors.trisaluslifesci.com/node/6736/ixbrl-viewer] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On November 14, 2022, MTAC and TriSalus issued a joint press release announcing the execution of the Merger Agreement." [https://investors.trisaluslifesci.com/node/6716/html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“MTAC”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) ..." [https://investors.trisaluslifesci.com/node/6836/html]

Source: https://trisaluslifesci.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

TriSalus Life Sciences is merging with MedTech Acquisition Corp (MTAC) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is TriSalus Life Sciences going public?

TriSalus Life Sciences has an approved merger with the SPAC MedTech Acquisition Corp (MTAC). Deal status: Closed (deSPAC).

Does TriSalus Life Sciences have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals